Compare Charter Communications Inc (CHTR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charter Communications Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Charter Communications Inc trades at $127.65 (market cap $16.16B), while Regeneron Pharmaceuticals Inc trades at $655.5 (market cap $69.52B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.3× Charter Communications Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while Charter Communications Inc pays none. Which is the better fit depends on your goals.
| CHTR | REGN | |
|---|---|---|
Market Cap | $16.16B | $69.52B |
Sector | Media | Health |
52-Week High | $398.11 | $812.27 |
52-Week Low | $125.54 | $542.52 |
Enterprise Value | $112.46B | $63.47B |
Dividend Yield | — | 0.57% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
